Trial Profile
A Prospective Randomized Multicenter Study Comparing the Safety and Efficacy of Renal Artery Stenting With/Without Distal Protection Device (AngioGuard) and With/Without the Use of a Platelet Aggregator Inhibitor (Abciximab-Reopro) (RESIST)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2014
Price :
$35
*
At a glance
- Drugs Abciximab (Primary)
- Indications Renal failure; Restenosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms RESIST
- 16 Dec 2014 New trial record